ISSN 2515-8260 Volume 05, Issue 01, 2018

Pharmacogenomics and personalized medicine: A Descriptive study of current trends and future perspective

Archana Dhyani,
Asst. Professor, School of Pharmacy, Graphic Era Hill University,
Dehradun, Uttarakhand India 248002

10.48047/ejmcm/v05/i01/74

Abstract:

At the nexus of genetics and healthcare, the powerful fields of pharmacogenomics and personalized medicine have evolved, revolutionizing both the prescription of pharmaceuticals and the provision of patient care. Pharmacogenomics receives attention because of its potential to enhance drug therapy and reduce negative side effects. Pharmacogenomic testing helps to identify genetic variations among people who are get affected drug response and metabolism. The goal of personalized medicine is to increase therapeutic efficacy while lowering the risk of adverse events by customizing a patient's course of therapy based on the genetic profile. Improvements in patient outcomes has become possible by pharmacogenomics' significant achievements in fields like oncology, psychiatry, and cardiovascular medicine. Prospects for pharmacogenomics and personalized medicine are very positive. Pharmacogenomic testing capabilities will increase because of the quick development of genomic technologies like high-throughput genotyping and next-generation sequencing. Additionally, pharmacogenomic data linkage with electronic medical records and decision support systems will improve clinical implementation. Personalized therapy suggestions can be created using artificial intelligence and machine learning algorithms after extensive analysis of patient data that considers clinical, genetic, and lifestyle aspects.

Keywords: Genomics, Drug Discovery, Phenotype, Genotype, Biomarkers, Pharmacology.

Introduction:

Pharmacogenomics and personalized medicine have gained popularity recently as a promising means of transforming the healthcare sector. Medical experts can now individually adapt medical treatments to individuals, maximizing efficacy and minimizing side effects, by combining genetic information with cutting-edge technologies. By moving away from a one-size-fits-all strategy and towards tailored therapies that consider a person's particular genetic makeup. Field of pharmacogenomics investigates how a person's genetic makeup affects how they react to

ISSN 2515-8260 Volume 05, Issue 01, 2018

medications. It seeks to pinpoint the genetic variants that affect medication metabolism, effectiveness, and toxicity. Healthcare professionals can choose appropriate medications, alter dosages, and create customized treatment programs by learning about these genetic markers. The ability to analyze a person's genetic profile on a larger scale is possible by improvements in DNA sequencing technologies and the dropping cost of genetic testing. This makes it possible for medical practitioners to pinpoint precise genetic markers linked to drug response. The interpretation of this genetic material has improved in accuracy and accessibility with the use of bioinformatics tools and databases. Drug development has greatly benefited by pharmacogenomics. To pinpoint patient subgroups that are more likely to respond favorably to treatments, pharmaceutical companies now include genetic data in early-stage clinical trials. Oncology is one discipline in personalized medicine that has made notable strides. Clinicians can pinpoint mutations that fuel the spread of cancer thanks to genomic analysis of tumors. Using this knowledge, tailored medicines are created, such as monoclonal antibodies and small chemical inhibitors, which specifically target cancer cells while preserving healthy tissues. The outcomes and survival rates of cancer patients have greatly improved because to precision medicine. The significance of pharmacogenomics in clinical practice is more frequently getting approvals from authorities. To promote the inclusion of pharmacogenetic testing in routine patient treatment, they have published guidelines and recommendations. To help healthcare professionals properly interpret and use genetic information, this involves identifying medications with strong genetic correlations, creating testing protocols, and offering decision support tools **(Cohen, N., & Frangiosa, T. 2008; Alam et al., 2017).**

New genetic markers related to medication response will be found as our understanding of the human genome expands. The development of genetic knowledge and the discovery of novel biomarkers is possible by ongoing research projects like the Human Genome Project and large-scale genomic studies. As a result, pharmacogenetic testing will be more accurate and precise, resulting in more individualized treatment plans. The subject of personalized medicine has a lot to gain from using artificial intelligence (AI) and machine learning (ML) technologies. These tools can examine enormous volumes of clinical and genetic data to find trends and create predictive models. Healthcare professionals may make data-driven decisions, forecast patient drug responses, and improve treatment regimens by utilizing AI and ML. It is anticipated that this technological integration would hasten the acceptance of personalized medicine **(Wadelius, M., & Alfirevic, A. 2011).**

Literature Review:

Pharmacogenomics is the scientific study of how a person's genetic composition affects how they respond to drugs. Pharmacogenomics has become a viable method for enhancing pharmacological therapy and reducing negative side effects because of the rapid advances in genomics and molecular biology. The goal of personalized medicine, which is closely related to pharmacogenomics, is to adapt medical therapies to the particulars of each patient.

Current Trends in Pharmacogenomics: The goal of pharmacogenomics is to create personalized medicine, in which therapeutic regimens are adapted to a patient's unique genetic makeup. Genetic differences that affect drug metabolism, efficacy, and safety are considered in this method. Healthcare professionals can choose medications and doses that are most likely to be efficient and secure for a certain patient by considering that person's genetic profile. The availability of cutting-edge genetic testing technology considerably aids Research and application in pharmacogenomics . Numerous genes linked to medication response may be efficiently and affordably analyzed using methods like next-generation sequencing (NGS) and genotyping arrays. Commercial pharmacogenomic tests have been created because of these developments, and they can offer useful information to inform decisions about what medications to prescribe. Pharmacogenomic testing is now into electronic health records (EHRs) and decision support systems by numerous healthcare systems and organizations. This enables access to genetic data and specialized recommendations for drug choice and dosage based on a patient's genetic profile for healthcare professionals. The goal of ongoing pharmacogenomics research is to find new genetic variations linked to drug response and to deepen our understanding of the intricate relationships between genes and medications. The need of training medical professionals about pharmacogenomics is rising. To guarantee that practitioners are educated about the concepts and uses of pharmacogenomics, training programs and educational resources are being created **(Schwartz, E. J., & Issa, A. M. 2017).**

Future Perspectives of Pharmacogenomics: The future of healthcare is quite promising because of pharmacogenomics and personalized therapy. These disciplines work to develop more effective and individualized therapies by customizing medical procedures and drugs to a patient's genetic profile and unique health traits. With the use of pharmacogenomics, medical professionals are now able to recognize genetic differences that may affect a person's response to medications. Future drug development will likely include genetic testing to help doctors choose the best treatments for each patient. By using this strategy, unpleasant responses will be reduced, and treatment effectiveness will rise. Pharmacogenomics can be included into the drug development process to help identify patient subgroups that are more likely to respond favorably to a certain medication. To lower the frequency of serious adverse events and enhance patient safety, pre-treatment genetic testing may someday become standard procedure. To calculate the ideal dosage of a medication, personalized medicine considers a patient's genetic profile, lifestyle, and other characteristics. Pharmacogenomic information can assist medical professionals in providing the ideal dosage for each patient, reducing the possibility of under- or overmedicating. A thorough understanding of a person's biological profile is understood by omics technologies like genomics, transcriptomics, proteomics, and metabolomics. Incorporating this data with pharmacogenomics permits individualized therapy choices and enhancing therapeutic results. Numerous complicated illnesses, including cancer, heart disease, and psychiatric problems, have a large hereditary component. The choice of targeted medicines can be influenced by pharmacogenomics, which can help identify the genetic markers linked to certain disorders. With this strategy, the trial-and-error process frequently connected to complex situations can be reduced and treatment response rates can be improved. Long-term healthcare cost optimization is a possibility with personalized therapy. Pharmacogenomics can improve healthcare systems' resource allocation and cost-effectiveness by decreasing the occurrence of adverse events, enhancing therapeutic efficacy, and avoiding ineffective medicines **(M Dias et al. 2012).**

Challenges and Limitations: By adapting medical therapies to a patient's genetic profile, personalized medicine and pharmacogenomics hold significant promise for enhancing patient care. The widespread adoption and success of these strategies will depend on how well they handle several obstacles and constraints. The human genome is still being fully characterized, and many genetic differences have not yet been connected to pharmacological responses. It is difficult to anticipate a person's reaction to a particular medicine because there isn't enough information available about all relevant genetic variants. Environmental factors are a major driver of drug response in addition to genetic variances. Diet, lifestyle, and other drugs, among other things, can affect a drug's efficacy and safety. Personalized medicine techniques have a substantial barrier in incorporating these intricate gene-environment connections. Personalized medicine and the application of pharmacogenomics present moral and legal issues. To make sure that genetic data is used in healthcare responsibly and ethically, concerns such patient privacy, informed consent, access to genetic information, and potential discrimination based on genetic profiles need to be carefully considered. It can be expensive and not available to all patients to include pharmacogenomic testing and personalized therapy into standard clinical practice. Healthcare institutions must create techniques to make genetic testing and interpretation more inexpensive and available to a larger population because they can be costly. Due to elements including heritage and ethnicity, genetic variances and medication responses can differ amongst groups. To prevent health disparities and guarantee equitable healthcare, it is essential to make sure that pharmacogenomic research and personalized medicine methods are inclusive and representative of varied communities **(Abul et al. 2014).**

Objective

To measure opinion about the pharmacogenomics and personalized medicine

Methodology

This study is descriptive in nature in which the data were obtained from the 193 respondents which includes patients with specific diseases, ethnic and racial groups, adverse drug reaction (ADR) cohorts and healthy volunteers. A checklist question was used to analyze and interpret the data. In a checklist question respondents choose “Yes” or “No” for all the questions.

Data Analysis and Interpretations:

Table 1 Pharmacogenomics and personalized medicine

SL No.	Pharmacogenomics and personalized medicine	Yes	% Yes	No	% No	Total
1	Pharmacogenomics examines how an individual's genetic makeup influences their response to medications.	181	93.78	12	6.22	193

2	Pharmacogenomics may enable personalized medicine by identifying genetic variations that can predict an individual's response to a specific medication.	147	76.17	46	23.83	193
3	Genetic variations can also impact an individual's ability to metabolize and eliminate drugs from their body.	150	77.72	43	22.28	193
4	Pharmacogenomics allows for the identification of genetic markers that increase the risk of specific ADRs.	166	86.01	27	13.99	193
5	Genetic information can help identify specific patient populations that are more likely to respond positively to a new drug.	154	79.79	39	20.21	193
6	Pharmacogenomics has significant implications for the management of chronic diseases, such as cardiovascular disorders, cancer, and psychiatric conditions.	183	94.82	10	5.18	193
7	Pharmacogenomics raises important ethical considerations regarding patient privacy, informed consent, and access to genetic testing.	159	82.38	34	17.62	193
8	Widespread implementation of pharmacogenomics ensures that healthcare professionals are trained in interpreting and utilizing genetic information effectively.	179	92.75	14	7.25	193

Table 1 shows the pharmacogenomics and personalized medicine. It was found that around 94.8% respondents accept that pharmacogenomics has significant implications for the management of chronic diseases, such as cardiovascular disorders, cancer, and psychiatric conditions. Additionally, pharmacogenomics examines how an individual's genetic makeup influences their response to medications (93.7%). Moreover, widespread implementation of pharmacogenomics ensures that healthcare professionals are trained in interpreting and utilizing genetic information effectively (92.7%). Pharmacogenomics allows for the identification of genetic markers that increase the risk of specific ADRs (86.0%). Pharmacogenomics raises important ethical considerations regarding patient privacy, informed consent, and access to genetic testing (82.3%). In addition, genetic information can help identify specific patient populations that are more likely to respond positively to a new drug (79.7%). However, genetic variations can also impact an individual's ability to metabolize and eliminate drugs from their body (77.7%). Lastly, pharmacogenomics may enable personalized medicine by identifying genetic variations that can predict an individual's response to a specific medication (76.1%).

Conclusion:

In conclusion, these have become ground-breaking areas of medicine that are reshaping the way we approach patient care and treatment. The present patterns in these fields show an increasing focus on knowing how genetic variants affect drug response and customizing treatments for unique people. The optimization of drug choice, dosage, and treatment strategies is possible by the integration of genomic data with clinical information by healthcare practitioners. Pharmacogenomics and personalized medicine have a bright future ahead of them. Genetic testing is becoming more widely available and more reasonably priced thanks to technological advancements like high-throughput genotyping and next-generation sequencing. This will make personalized medical techniques more widely adopted, improving patient outcomes and lowering pharmacological adverse responses. Our capacity to analyze sizable datasets and precisely anticipate drug reactions will also be improved by the incorporation of artificial intelligence and machine learning technologies. This will speed up the creation of more focused treatments and the identification of fresh pharmacological targets.

References:

- Abul-Husn, N. S., Owusu Obeng, A., Sanderson, S. C., Gottesman, O., & Scott, S. A. (2014). Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and personalized medicine, 227-240.
- Alam, M., Mittal, A., & Chawla, D. (2017). Evaluating patients' perception towards generic and branded medicines: A segmentation approach. *Journal Of Generic Medicines*, *13*(4), 184-192. doi: 10.1177/1741134317737925
- Cohen, N., & Frangiosa, T. (2008). Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine: An Industry Perspective. Pharmacogenomics and personalized medicine, 1-26.
- Crews, K. R., Hicks, J. K., Pui, C. H., Relling, M. V., & Evans, W. E. (2012). Pharmacogenomics and individualized medicine: translating science into practice. Clinical Pharmacology & Therapeutics, 92(4), 467-475.
- E Laing, R., Hess, P., Shen, Y., Wang, J., & X Hu, S. (2011). The role and impact of SNPs in pharmacogenomics and personalized medicine. Current drug metabolism, 12(5), 460-486.
- J Diaz, F., Yeh, H. W., & de Leon, J. (2012). Role of statistical random-effects linear models in personalized medicine. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 10(1), 22-32.
- Klein, M. E., Parvez, M. M., & Shin, J. G. (2017). Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. Journal of pharmaceutical sciences, 106(9), 2368-2379.
- M Dias, M., Depala, K., M Ward, H., B Ward, M., J Sorich, M., Anderson, C., & A McKinnon, R. (2012). Reforming pharmaceutical education to enhance the global uptake of pharmacogenomics and personalized medicine. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 10(3), 231-238.
- Maliepaard, M., Nofziger, C., Papaluca, M., Zineh, I., Uyama, Y., Prasad, K., ... & Paulmichl, M. (2013). Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nature Reviews Drug Discovery, 12(2), 103-115.

- N Al-Eitan, L., & A Haddad, Y. (2014). Emergence of pharmacogenomics in academic medicine and public health in Jordan: History, present state and prospects. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 12(3), 167-175.
- Paci, D., & Ibarreta, D. (2009). Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 7(4), 284-296.
- Schwartz, E. J., & Issa, A. M. (2017). The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine. Personalized Medicine, 14(1), 27-35.
- Tutton, R., & Jamie, K. (2013). Personalized medicine in context: social science perspectives. Drug Discovery Today: Therapeutic Strategies, 10(4), e183-e187.
- Unertl, K. M., Jaffa, H., Field, J. R., Price, L., & Peterson, J. F. (2015). Clinician perspectives on using pharmacogenomics in clinical practice. Personalized medicine, 12(4), 339-347.
- Wadelius, M., & Alfirevic, A. (2011). Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing. Genome medicine, 3(12), 78.